

VERMILLION CORPORATE FACT SHEET

CORPORATE OVERVIEW

Vermillion, Inc. (VRML) is focused on the discovery, development, and commercialization of novel, high-value diagnostic tests that provide physicians with information to better manage and improve patient care. Headquartered in Fremont, California, the company is developing diagnostic products in a variety of clinical areas including cardiology, oncology and hematology.

PRODUCT PIPELINE

CARDIOVASCULAR DISEASE

Peripheral Artery Disease (PAD) Blood Test

In collaboration with researchers at Stanford University, Vermillion is developing a novel blood test to stratify an individual's risk of developing PAD, a serious disease estimated to affect up to 12 million Americans.

The test – which has been evaluated in four studies comprising almost 1,000 patients – simultaneously evaluates four specific biomarkers for PAD and creates an index score. Vermillion studies have shown that patients with a high index score are seven times more likely to have PAD than patients with a low index score.

Additionally, in late 2007, Vermillion completed a 540-patient clinical study evaluating the ability of its multi-marker panel to stratify individuals into high and low risk groups for PAD. These results have been accepted for publication in a peer-reviewed clinical journal and are expected to be published in the first half of 2008.

OVARIAN CANCER

The company is developing three ovarian cancer blood tests which have the potential to:

- Improve the ability to distinguish between benign and malignant tumors
- Diagnose early-stage disease
- Predict prognosis and recurrence

Ovarian Tumor Triage Test

The most advanced of Vermillion's ovarian diagnostic programs is the Ovarian Tumor Triage Test, which utilizes a panel of biomarkers to help identify women with cancer so they can be referred directly to a gynecologic oncologist for their initial surgery, thus improving survival rates and potentially reducing the number of second surgeries performed.

Vermillion intends to submit clinical trial data on the Ovarian Tumor Triage Test to the U.S. Food and Drug Administration for clearance as an *in vitro* diagnostic test in the coming months.

Ovarian Cancer High-Risk Triage Test

More than 10 million women are considered to be at high risk for ovarian cancer based on several risk factors, including family history. Vermillion is applying its biomarker technology capabilities to develop a simple blood test

RECENT CORPORATE HIGHLIGHTS

Ovarian Cancer Program:

- Renewed long-standing collaboration with Johns Hopkins University on the development of biomarkers that can be applied toward disease detection, classification and monitoring of prevalent cancers, including ovarian, prostate and breast. Company will have access to exclusive commercial rights to the discoveries made through the partnership. (January 2008)

Peripheral Artery Disease Program (PAD):

- Completed internal validation of a blood-based assay for the detection of PAD in partnership with Quest Diagnostics. (January 2008)
- Published research in *Circulation* that detailed how Vermillion researchers showed that elevated levels of beta-2 microglobulin are correlated to the presence and severity of PAD. (November 2007)

Corporate Development:

- Received certificate of issuance from U.S. Patent and Trademark Office for Patent No. 7,297,556 for aiding diagnosis of nephrotic syndrome. (November 2007)
- Received certificate of reissuance from U.S. Patent and Trademark Office for Patent No. 6,734,022, which is directed to a fundamental process of SELDI mass spectrometry. (November 2007)
- Announced license agreement with The Ohio State University Research Foundation and The Ohio State University (OSU), to permit OSU to provide a proteomics-based diagnostic test to detect thrombotic thrombocytopenic purpura. (November 2007)

KEY INFORMATION

- Nasdaq: VRML
- 63,801,971 common shares outstanding (as of 12/31/07)
- 30 employees (as of 12/31/07)

Vermillion, Inc.
6611 Dumbarton Circle
Fremont, California 94555
Tel: 1-888-864-3770
Fax: 1-510-505-2101

that could be used to triage these patients and allow detection of the disease at its earliest stages, when treatment is more effective and survival rates are higher.

Results from a recent study presented at the 15th International Meeting of the European Society of Gynecologic Oncology (ESGO) found that Vermillion's panel of biomarkers in combination with CA-125, a commonly used tumor marker for ovarian cancer, could more accurately identify early-stage ovarian cancer than could CA-125 alone. Vermillion plans to initiate additional studies for the test in the coming year.

Ovarian Cancer Prognosis Test

Vermillion is developing a blood test to help predict prognosis of ovarian cancer, which may help patients and physicians make more informed treatment decisions. A study presented at ESGO in October 2007 found that Vermillion's biomarker panel could accurately and with statistical significance predict women with ovarian cancer who had good prognosis from those who did not.

BLOOD DISORDERS

Thrombotic Thrombocytopenic Purpura (TTP) Test

In conjunction with The Ohio State University (OSU) Research Foundation, Vermillion developed a test for the diagnosis and clinical evaluation of TTP, a devastating blood disorder that causes abnormal clotting and carries the risk of neurologic, renal and cardiac dysfunction and even death. Our test utilizes mass spectrometry to help physicians make the correct diagnosis, initiate timely treatment, evaluate response to therapy and predict the risk of recurrence in patients with TTP. Vermillion currently licenses the TTP assay to OSU for availability as a laboratory developed test.

STRATEGIC PARTNERSHIPS

Vermillion has collaborations with leading academic and research institutions throughout the world, including:

- The Johns Hopkins School of Medicine
- The University of Texas M. D. Anderson Cancer Center
- Stanford University
- Rigshospitalet (Copenhagen)
- University of Kentucky
- The Ohio State University Research Foundation

The company has a strategic alliance with Quest Diagnostics to develop and commercialize proteomics-based diagnostic tests. To date, Quest has chosen two of Vermillion's tests for development – the ovarian tumor triage test and the peripheral artery disease blood test.

Additionally, Vermillion has a partnership with Bio-Rad Laboratories to purchase SELDI instruments for the continued development of Vermillion's diagnostics business. The companies are also collaborating to identify SELDI customers interested in partnering with Vermillion to commercialize biomarker discoveries.

MANAGEMENT TEAM

Gail S. Page

President and Chief Executive Officer

Eric T. Fung, M.D., Ph.D.

Vice President, Chief Scientific Officer

Lee Lomas, Ph.D.

Senior Director, Biology Research and Development

Steve Lundy

Senior Vice President, Sales & Marketing

Simon C. Shorter, Ph.D.

Vice President, Corporate Business Development

BOARD OF DIRECTORS

James L. Rathmann

Chairman of the Board

John A. Young

Lead Outside Director

Gail S. Page

President and Chief Executive Officer

Judy Bruner

Executive Vice President, Administration and Chief Financial Officer, SanDisk Corporation

James S Burns

President and CEO, Entremed, Inc.

Michael J. Callaghan

Former Senior Vice President, MDS Capital Corporation

Kenneth J. Conway

President, Starfire Ventures

Rajen K. Dalal

Chief Executive Officer, Aviiir, Inc.

SCIENTIFIC ADVISORY BOARD

Robert C. Bast, Jr., M.D.

University of Texas M.D. Anderson Cancer Center

Daniel W. Chan, Ph.D., DABCC, FACR

Johns Hopkins University School of Medicine

Ian Jacobs, M.D., FRCOG

University College London

Joyce G. Schwartz, M.D.

Quest Diagnostics

William Wallen, Ph.D.

Idexx Laboratories